Introduction to Aliskiren
Aliskiren, a member of the renin inhibitors drug class, is primarily used to treat high blood pressure. It is marketed under the brand name Tekturna and works by blocking the action of renin, an enzyme involved in the production of angiotensin I, a precursor to angiotensin II, which constricts blood vessels and increases blood pressure.
Global Aliskiren Market Overview
The global aliskiren market is expected to grow at a moderate pace over the forecast period. Key drivers include the increasing effectiveness of aliskiren in controlling hypertension, its compatibility with all classes of current antihypertensive drugs, and an increase in government initiatives and health awareness[4].
Market Segmentation
The global aliskiren market is segmented based on type, application, and geography.
By Type
- 150 mg Tablet: This is one of the most common dosages and has a significant impact on the market.
- 300 mg Tablet: Another key dosage, often prescribed for patients who require higher doses.
- Other: Includes other formulations and dosages of aliskiren[4].
By Application
- Hospital: A major segment, as hospitals are primary users of aliskiren for treating hypertensive patients.
- Drug Store: Retail pharmacies also play a crucial role in the distribution of aliskiren.
- Other: Includes clinics, private practices, and other healthcare facilities[4].
By Geography
- North America: Expected to grow at the highest CAGR during the forecast period due to the presence of major players and increasing adoption.
- Europe: A significant market due to high healthcare standards and awareness.
- Asia Pacific: Growing rapidly due to increasing healthcare expenditure and a large patient population.
- Rest of the World: Includes Latin America, Middle East, and other regions with potential for growth[4].
Market Size and Forecast
The global aliskiren market is projected to grow significantly from 2021 to 2028. The market size is increasing due to the effectiveness of aliskiren in controlling hypertension and its ability to be combined with other antihypertensive drugs. The market is expected to grow at a moderate CAGR, driven by increasing health awareness and government initiatives[4].
Key Drivers and Restraints
Drivers
- Increasing Effectiveness: Aliskiren's ability to control hypertension effectively and its compatibility with other antihypertensive drugs are major drivers.
- Government Initiatives: Increased government focus on healthcare and initiatives to reduce hypertension rates.
- Health Awareness: Rising awareness about the importance of blood pressure control[4].
Restraints
- High Cost: The components of aliskiren medicines are costly, which constrains market growth.
- Production Challenges: Poor absorption from the gastrointestinal tract, low bioavailability, short half-life, and low potency hinder the development and production of aliskiren[4].
Price Projections
The cost of aliskiren varies based on the dosage and pharmacy.
Current Pricing
- 150 mg Oral Tablet: Around $200 for a supply of 30 tablets, with a per-unit cost ranging from $6.68 to $6.96[2].
- 300 mg Oral Tablet: Approximately $250 for a supply of 30 tablets, with a per-unit cost ranging from $8.34 to $8.70[2].
Future Pricing Trends
Given the high cost of components and production challenges, prices may remain relatively stable or see moderate increases. However, the introduction of generic versions could potentially lower prices. Generic entry typically leads to a decline in drug prices, especially if multiple generic entrants join the market[5].
Competitive Landscape
The global aliskiren market is competitive, with several key players contributing to its growth.
Major Players
- Noden Pharma
- LGM Pharma
- Cayman
- Vitae-GSK
- Daiichi Sankyo
- Novartis
- Merck-Frost
- Mitsubishi-Tanabe
- Takeda
- Cadila Healthcare[4].
These companies are involved in various strategies such as partnerships, collaborations, and agreements to enhance their market presence and develop new products.
Regional Analysis
North America
Expected to dominate the global aliskiren market due to the presence of major pharmaceutical companies and a well-established healthcare system[4].
Europe
A significant market with high healthcare standards and a large patient population.
Asia Pacific
Growing rapidly due to increasing healthcare expenditure and a large population base.
Rest of the World
Includes regions like Latin America and the Middle East, which have potential for growth but face challenges such as limited healthcare infrastructure and economic constraints.
Technological and Regulatory Trends
Technological Trends
Advancements in drug delivery systems and the development of more bioavailable formulations could improve the efficacy and patient compliance of aliskiren[3].
Regulatory Trends
Regulatory bodies are focusing on reducing drug prices and increasing access to affordable medicines. Initiatives such as the Comprehensive Plan for Addressing High Drug Prices by the U.S. Department of Health and Human Services aim to promote competition and reduce barriers to generic drug entry[5].
Consumer Behavior Analysis
Patients and healthcare providers are increasingly seeking effective and affordable treatments for hypertension. The demand for personalized medicines and better diagnostic facilities is also driving the market. However, the high cost of aliskiren remains a significant barrier for many patients[4].
COVID-19 Impact
The COVID-19 pandemic has had a mixed impact on the aliskiren market. While it has highlighted the importance of managing chronic conditions like hypertension, supply chain disruptions and economic constraints have also affected the market. The pandemic has accelerated the need for remote healthcare services and telemedicine, which could influence the distribution and prescription patterns of aliskiren[1].
Key Takeaways
- The global aliskiren market is driven by its effectiveness in controlling hypertension and compatibility with other antihypertensive drugs.
- High costs and production challenges are significant restraints.
- North America is expected to dominate the market due to the presence of major players.
- Technological advancements and regulatory initiatives are crucial for market growth.
- Consumer demand for affordable and effective treatments is increasing.
FAQs
1. What is the primary use of aliskiren?
Aliskiren is primarily used to treat high blood pressure by inhibiting the action of renin, an enzyme involved in the production of angiotensin I.
2. What are the common dosages of aliskiren?
The common dosages of aliskiren are 150 mg and 300 mg oral tablets.
3. How much does aliskiren typically cost?
The cost of aliskiren can range from around $200 for a 30-tablet supply of 150 mg tablets to approximately $250 for a 30-tablet supply of 300 mg tablets.
4. Which region is expected to dominate the global aliskiren market?
North America is expected to dominate the global aliskiren market due to the presence of major pharmaceutical companies and a well-established healthcare system.
5. What are the key restraints to the growth of the aliskiren market?
The high cost of the components of aliskiren medicines and production challenges such as poor absorption, low bioavailability, and short half-life are significant restraints to market growth.
Cited Sources:
- Cognitivemarketresearch.com: Aliskiren Market Report 2024 (Global Edition)
- Drugs.com: Aliskiren Prices, Coupons, Copay Cards & Patient Assistance
- Datamintelligence.com: Renin-Inhibitors Market Size, Share, Industry, Forecast and outlook (2023-2030)
- Verifiedmarketresearch.com: Aliskiren Market Size, Share, Scope, Trends, Opportunities & Forecast
- Aspe.hhs.gov: COST OF GENERIC DRUG DEVELOPMENT AND APPROVAL FINAL REPORT DECEMBER 31, 2021
